Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Marley Spoon Group SE M&A Activity 2024

Jan 31, 2024

9329_tar_2024-01-31_68398dc6-2707-4f2a-b4db-46f05488e2e8.html

M&A Activity

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 5779B

Marley Spoon Group SE

31 January 2024

Marley Spoon to acquire US leading doctor designed meal brand bistroMD

EQS-Media / 31.01.2024

Marley Spoon Group SE, a leading global direct-to-consumer meal provider, signed an agreement for the acquisition of bistroMD, the leading doctor-designed ready-to-eat meal plan in the US, as a first step of previously announced growth and consolidation strategy, adding €35m in revenue (based on unaudited management reports).  With this acquisition, the company entered the large and growing RTE market in the US at scale and came two years after the acquisition of Chefgood, our Australia-based RTE brand. 

BistroMD was founded in 2005 by a husband and wife team, Edward and Dr. Caroline Cederquist, who followed their passion for delivering chef-quality food, balanced nutrition, and adequate lean protein for convenience and health-conscious consumers focused on weight loss and special dietary needs. With bistroMD consumers can conveniently order meal plans that are designed to support, amongst others, weight loss, a healthy heart, Keto diets, diabetic needs, or menopause. More and more Americans recognize that the food you eat has a big impact on your health, and food as a medicine is becoming top of mind to consumers. Marley Spoon believes that bistroMD is well-positioned to serve this growing consumer need. Furthermore, the integration into the Marley Spoon platform is expected to generate significant synergies and performance improvements.

Fabian Siegel, CEO & Founder of Marley Spoon, comments: "We are impressed by the strong brand and customer-focused organization that founder Ed Cederquist and his team have built over the past 19 years. We are committed to ensuring that bistroMD continues to flourish and grow as part of the Marley Spoon platform, and we welcome Ed and his team to Marley Spoon." Ed Cerderquist, CEO and Founder of bistroMD added: "Bringing bistroMD to this next stage of growth and development is an exciting endeavor. BistroMD and its customer base will highly benefit from the technology, data, and synergies that the Marley Spoon platform is expected to provide. I started bistroMD with the vision of making healthy eating easy for all, and I am looking forward to driving this vision forward, together with the Marley Spoon team." 

End of Media Release


Issuer: Marley Spoon Group SE

Key word(s): Services

31.01.2024 CET/CEST Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com


Language: English
Company: Marley Spoon Group SE
9 Rue de Bitbourg
1273 Luxembourg
Luxemburg
E-mail: [email protected]
Internet: www.marleyspoongroup.com
ISIN: LU2380748603, LU2380748785
WKN: A3C81B
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Munich, Stuttgart
EQS News ID: 1827369
End of News EQS Media

1827369  31.01.2024 CET/CEST

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUAAVRSOUAOAR